{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T05:04:29Z","timestamp":1717045469962},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.leukres.2003.12.002","type":"journal-article","created":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T20:16:34Z","timestamp":1086984994000},"page":"813-819","source":"Crossref","is-referenced-by-count":9,"title":["Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group"],"prefix":"10.1016","volume":"28","author":[{"given":"William R","family":"Friedenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isadore","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Paietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob M","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra J","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Kendrith M","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W","family":"Schnetzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2003.12.002_BIB1","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukemia","volume":"16","author":"Rozman","year":"1995","journal-title":"N. Eng. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.leukres.2003.12.002_BIB2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10428199909083394","article-title":"Multidrug resistance in chronic lymphocytic leukemia","volume":"34","author":"Friedenberg","year":"1999","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2003.12.002_BIB3","first-page":"87","article-title":"Mechanisms of multidrug resistance","volume":"948","author":"Bradley","year":"1988","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.leukres.2003.12.002_BIB4","doi-asserted-by":"crossref","unstructured":"Dalton WS, Grogan TM. Does p-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it? J Natl Cancer Inst 1991;83:80\u20131.","DOI":"10.1093\/jnci\/83.2.80"},{"key":"10.1016\/j.leukres.2003.12.002_BIB5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.1989.7.4.415","article-title":"Drug-resistance in multiple myeloma and non-Hodgkin\u2019s lymphoma: detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy","volume":"7","author":"Dalton","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.12.002_BIB6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1182\/blood.V73.3.747.747","article-title":"Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation","volume":"73","author":"Dalton","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.12.002_BIB7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0065-2571(89)90106-4","article-title":"Studies on drug resistance in chronic lymphocytic leukemia","volume":"29","author":"Silber","year":"1989","journal-title":"Adv. Enzyme Reg."},{"key":"10.1016\/j.leukres.2003.12.002_BIB8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.1990.tb07876.x","article-title":"Expression of the multiple drug resistance gene (MDR-1) and epitope masking in chronic lymphatic leukaemia","volume":"76","author":"Cumber","year":"1990","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.12.002_BIB9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2141.1991.tb08006.x","article-title":"Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL)","volume":"79","author":"Shustik","year":"1991","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.12.002_BIB10","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.V79.6.1496.1496","article-title":"High expression of the MDR, mutltidrug-resistance gene in advanced-stage chronic lymphocytic leukemia","volume":"79","author":"Sonneveld","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.12.002_BIB11","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood.V82.11.3452.3452","article-title":"P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1\/MDR3 gene expression","volume":"82","author":"El Rouby","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.12.002_BIB12","first-page":"216","article-title":"Is the MDR1 gene relevant in chronic lymphocytic leukemia?","volume":"4","author":"Holmes","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.12.002_BIB13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1991.tb08610.x","article-title":"The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia","volume":"77","author":"Michieli","year":"1991","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2003.12.002_BIB14","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/85.21.1751","article-title":"Activity of p-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay","volume":"85","author":"Ludescher","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2003.12.002_BIB15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0145-2126(93)90041-I","article-title":"Common expression of the multidrug resistance marker p-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance","volume":"17","author":"Sparrow","year":"1993","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2003.12.002_BIB16","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/1097-0142(19930515)71:10<2983::AID-CNCR2820711016>3.0.CO;2-1","article-title":"Modified vincristine, doxorubicin, and dexamethasone regimen in the treatment of resistant or relapsed chronic lymphocytic leukemia","volume":"71","author":"Friedenberg","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2003.12.002_BIB17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0140-6736(92)92353-H","article-title":"Modulation of multidrug-resistant multiple myeloma by cyclosporine","volume":"340","author":"Sonneveld","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2003.12.002_BIB18","first-page":"23","article-title":"Multidrug resistance: clinical relevance in acute leukemia","volume":"7","author":"List","year":"1993","journal-title":"Oncology"},{"key":"10.1016\/j.leukres.2003.12.002_BIB19","first-page":"309","article-title":"Multidrug resistance (MDR) in chronic lymphocytic leukemia (CLL)","volume":"13","author":"Friedenberg","year":"1994","journal-title":"Proc. ASCO"},{"key":"10.1016\/j.leukres.2003.12.002_BIB20","first-page":"179","article-title":"Multidrug resistance (MDR) in chronic lymphocytic leukemia (CLL)","volume":"14","author":"Friedenberg","year":"1995","journal-title":"Proc. ASCO"},{"key":"10.1016\/j.leukres.2003.12.002_BIB21","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/0277-5379(91)90435-G","article-title":"Resistance modification by PSC-833, a novel nonimmunosuppressive cyclosporine-A","volume":"27","author":"Twentyman","year":"1991","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.leukres.2003.12.002_BIB22","first-page":"4226","article-title":"In vivo circumvention of p-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC-833","volume":"51","author":"Boesch","year":"1991","journal-title":"Cancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2003.12.002_BIB23","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00001813-199409001-00098","article-title":"SDZ PSC-833 in combination with doxorubicin: a phase I and pharmacologic study in solid tumors","volume":"5","author":"Giaccone","year":"1994","journal-title":"Anticancer Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2003.12.002_BIB24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00001813-199409001-00097","article-title":"A phase I trial of doxorubicin (DOX) and PSC-833, a modulator of multidrug resistance (MDR)","volume":"5","author":"Erlichman","year":"1994","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.leukres.2003.12.002_BIB25","unstructured":"Case Jr DC, Jain V, Stiff P, Jansen J, Stewart AK, Shurafa M, et al. Phase II study of PSC 833 (PSC) and VAD chemotherapy in patients with VAD-refractory multiple myeloma (MM). Therapy of Chronic lymphocytic Leukemia and Multiple Myeloma. Abstract 427. Poster Board #\/Session: 427-I, p. 105a."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2003.12.002_BIB26","first-page":"662a","article-title":"Phase I study of the chemosensitizer SDZ PSC-833 in combination with VAD chemotherapy to reverse multidrug resistance","volume":"88","author":"Dalton","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.12.002_BIB27","first-page":"2005","article-title":"A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC-833 in combination with doxorubicin in patients with solid tumors","volume":"3","author":"Giaccone","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2003.12.002_BIB28","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","article-title":"National Cancer Institute Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment","volume":"87","author":"Cheson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.12.002_BIB29","first-page":"968","article-title":"Significantly lower p-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses","volume":"8","author":"Paietta","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2003.12.002_BIB30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0268-960X(95)90039-X","article-title":"Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro","volume":"9","author":"Paietta","year":"1995","journal-title":"Blood Rev."},{"issue":"9","key":"10.1016\/j.leukres.2003.12.002_BIB31","first-page":"3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses","volume":"91","author":"Kitada","year":"1998","journal-title":"J. Article Multicenter Study Blood"},{"key":"10.1016\/j.leukres.2003.12.002_BIB32","doi-asserted-by":"crossref","unstructured":"American Society of Clinical Oncology Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471\u2013508.","DOI":"10.1200\/JCO.1994.12.11.2471"},{"key":"10.1016\/j.leukres.2003.12.002_BIB33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical studies","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.leukres.2003.12.002_BIB34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.12.002_BIB35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.leukres.2003.12.002_BIB36","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.V98.12.3212","article-title":"Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group Study. Clinical observations, interventions, and therapeutic trials","volume":"98","author":"List","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2003.12.002_BIB37","doi-asserted-by":"crossref","unstructured":"Baer et al. Phase 3 Study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood, 15 August 2002;100:1225\u201332.","DOI":"10.1182\/blood.V100.4.1224.h81602001224_1224_1232"},{"key":"10.1016\/j.leukres.2003.12.002_BIB38","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2001.19.12.2975","article-title":"Phase II study of paclitaxel and valspodar (PSC-833) in refractory ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"19","author":"Fracasso","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2003.12.002_BIB39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02785844","article-title":"Transforming growth factor-\u03b2 and multidrug resistance in chronic lymphocytic leukemia","volume":"16","author":"Friedenberg","year":"1999","journal-title":"Med. Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603004144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212603004144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T11:58:23Z","timestamp":1585828703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212603004144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0145212603004144"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2003.12.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}